BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15894863)

  • 1. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.
    Inukai T; Yoshida N; Wakabayashi S; Inukai Y; Matsutomo R; Takanashi K; Nakamachi T; Takebayashi K; Aso Y; Takahashi K
    Am J Med Sci; 2005 May; 329(5):222-7. PubMed ID: 15894863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superoxide dismutase activity of the captopril-iron complex.
    Jay D; Cuella A; Jay E
    Mol Cell Biochem; 1995 May; 146(1):45-7. PubMed ID: 7651376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free radical scavenging properties of alacepril metabolites and lisinopril.
    Noda Y; Mori A; Packer L
    Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):125-36. PubMed ID: 9226747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors.
    Chopra M; Beswick H; Clapperton M; Dargie HJ; Smith WE; McMurray J
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):330-40. PubMed ID: 1378110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfhydryl group in angiotensin converting enzyme inhibitors and superoxide radical formation.
    Mehta JL; Nicolini FA; Lawson DL
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):847-9. PubMed ID: 1703610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.
    Ibrahim MA; Ashour OM; Ibrahim YF; El-Bitar HI; Gomaa W; Abdel-Rahim SR
    Pharmacol Res; 2009 Nov; 60(5):373-81. PubMed ID: 19467331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
    Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
    Westlin W; Mullane K
    Circulation; 1988 Jun; 77(6 Pt 2):I30-9. PubMed ID: 2836109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
    Fukuda D; Enomoto S; Nagai R; Sata M
    Biomed Pharmacother; 2009 Dec; 63(10):754-61. PubMed ID: 19304450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
    Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.
    Kitakaze M; Asanuma H; Funaya H; Node K; Takashima S; Sanada S; Asakura M; Ogita H; Kim J; Hori M
    J Am Coll Cardiol; 2002 Jul; 40(1):162-6. PubMed ID: 12103271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
    Kawata T; Daimon M; Hasegawa R; Teramoto K; Toyoda T; Sekine T; Yamamoto K; Uchida D; Himi T; Yoshida K; Komuro I
    Am Heart J; 2006 Apr; 151(4):798.e9-15. PubMed ID: 16569537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
    Inoue A; Babazono T; Iwamoto Y
    Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.